Subscribe
shutterstock_1170053383casimiro-pt
Casimiro PT / Shutterstock.com
30 November 2020EuropeRory O'Neill

MSF urges EU to rid market of ‘avoidable suffering’ from SPCs

Médecins Sans Frontières (MSF) has warned that the European Commission’s commitment to the supplementary protection certificate (SPC) system risks undermining its promise to improve drug accessibility.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
MSF challenges Gilead patent application in China
21 December 2017   Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.
Generics
Lawyers warn of Irish Sea split over SPCs
17 December 2020   The UK is facing a divergence in supplementary protection certificate regulations across the Irish Sea post-Brexit.
Africa
MSF urges South Africa to open access to COVID-19 generics
10 February 2022   Humanitarian organisation Médecins Sans Frontières has called for the South African government to seek the revocation of COVID-19-related patents granted to Eli Lilly and Moderna.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Asia
MSF challenges Gilead patent application in China
21 December 2017   Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.
Generics
Lawyers warn of Irish Sea split over SPCs
17 December 2020   The UK is facing a divergence in supplementary protection certificate regulations across the Irish Sea post-Brexit.
Africa
MSF urges South Africa to open access to COVID-19 generics
10 February 2022   Humanitarian organisation Médecins Sans Frontières has called for the South African government to seek the revocation of COVID-19-related patents granted to Eli Lilly and Moderna.

More on this story

Asia
MSF challenges Gilead patent application in China
21 December 2017   Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.
Generics
Lawyers warn of Irish Sea split over SPCs
17 December 2020   The UK is facing a divergence in supplementary protection certificate regulations across the Irish Sea post-Brexit.
Africa
MSF urges South Africa to open access to COVID-19 generics
10 February 2022   Humanitarian organisation Médecins Sans Frontières has called for the South African government to seek the revocation of COVID-19-related patents granted to Eli Lilly and Moderna.

More features

GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks
Teva fights for re-listing of inhaler patents at US appeals court
CRISPR patents revoked following Nobel Prize winners’ withdrawal
White & Case hires experienced litigator from A&O Shearman
President Trump 2.0: Five major areas to watch